JP2002533123A5 - - Google Patents

Download PDF

Info

Publication number
JP2002533123A5
JP2002533123A5 JP2000591190A JP2000591190A JP2002533123A5 JP 2002533123 A5 JP2002533123 A5 JP 2002533123A5 JP 2000591190 A JP2000591190 A JP 2000591190A JP 2000591190 A JP2000591190 A JP 2000591190A JP 2002533123 A5 JP2002533123 A5 JP 2002533123A5
Authority
JP
Japan
Prior art keywords
recombinant
pneumoniae
antibodies reactive
protein
immunization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000591190A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002533123A (ja
JP4761623B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA1999/001218 external-priority patent/WO2000039299A2/en
Publication of JP2002533123A publication Critical patent/JP2002533123A/ja
Publication of JP2002533123A5 publication Critical patent/JP2002533123A5/ja
Application granted granted Critical
Publication of JP4761623B2 publication Critical patent/JP4761623B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000591190A 1998-12-23 1999-12-20 新規連鎖球菌抗原 Expired - Fee Related JP4761623B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11380098P 1998-12-23 1998-12-23
US60/113,800 1998-12-23
PCT/CA1999/001218 WO2000039299A2 (en) 1998-12-23 1999-12-20 Streptococcus antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010026521A Division JP5039802B2 (ja) 1998-12-23 2010-02-09 新規連鎖球菌抗原

Publications (3)

Publication Number Publication Date
JP2002533123A JP2002533123A (ja) 2002-10-08
JP2002533123A5 true JP2002533123A5 (enExample) 2007-01-25
JP4761623B2 JP4761623B2 (ja) 2011-08-31

Family

ID=22351610

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000591190A Expired - Fee Related JP4761623B2 (ja) 1998-12-23 1999-12-20 新規連鎖球菌抗原
JP2010026521A Expired - Fee Related JP5039802B2 (ja) 1998-12-23 2010-02-09 新規連鎖球菌抗原

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010026521A Expired - Fee Related JP5039802B2 (ja) 1998-12-23 2010-02-09 新規連鎖球菌抗原

Country Status (29)

Country Link
EP (2) EP2261358B1 (enExample)
JP (2) JP4761623B2 (enExample)
KR (4) KR100891398B1 (enExample)
CN (3) CN100398653C (enExample)
AP (1) AP2001002199A0 (enExample)
AR (1) AR029322A1 (enExample)
AT (1) ATE394489T1 (enExample)
AU (1) AU1764900A (enExample)
BR (1) BR9916477A (enExample)
CA (1) CA2356836C (enExample)
CL (1) CL2009002037A1 (enExample)
CY (3) CY1108223T1 (enExample)
CZ (2) CZ303675B6 (enExample)
DE (1) DE69938670D1 (enExample)
DK (3) DK1950302T3 (enExample)
EA (1) EA007409B1 (enExample)
ES (3) ES2480417T3 (enExample)
HU (1) HU229664B1 (enExample)
IL (3) IL143905A0 (enExample)
MX (1) MXPA01006427A (enExample)
NO (1) NO330800B1 (enExample)
NZ (1) NZ512574A (enExample)
OA (1) OA11736A (enExample)
PL (3) PL206576B1 (enExample)
PT (3) PT1950302E (enExample)
TR (2) TR200102497T2 (enExample)
UY (1) UY25877A1 (enExample)
WO (1) WO2000039299A2 (enExample)
ZA (1) ZA200105114B (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228497B1 (en) 1998-02-20 2013-03-28 Id Biomedical Corp Quebec Group b steptococcus antigens
EP1801218A3 (en) * 1998-07-27 2007-10-10 Sanofi Pasteur Limited Nucleic acids and proteins from streptococcus pneumoniae
US20030134407A1 (en) 1998-07-27 2003-07-17 Le Page Richard William Falla Nucleic acids and proteins from Streptococcus pneumoniae
PT1140157E (pt) 1998-12-21 2009-05-06 Medimmune Inc Proteínas de streptococcus pneumoniae e fragmentos imunogénicos para vacinas
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
CN100398653C (zh) * 1998-12-23 2008-07-02 益得生物医学公司 新颖的链球菌抗原
US6866855B2 (en) 2000-06-12 2005-03-15 University Of Saskatchewan Immunization of dairy cattle with GapC protein against Streptococcus infection
DK1294771T3 (da) 2000-06-12 2008-12-15 Univ Saskatchewan Kimært GapC-protein fra Streptococcus og anvendelse deraf til vaccinering og diagnosticering
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
CA2413450C (en) 2000-06-20 2014-02-18 Shire Biochem Inc. Streptococcus antigens
US7074415B2 (en) 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
AU2002242549A1 (en) * 2001-03-30 2002-10-15 Shire Biochem Inc. Streptococcus pyogenes antigens and corresponding dna fragments
US7393536B2 (en) 2001-07-06 2008-07-01 Id Biomedical Corporation Group B Streptococcus antigens and corresponding DNA fragments
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
AU2002351623A1 (en) * 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
EP1601770B1 (en) 2003-03-04 2009-09-02 Intercell AG Streptococcus pyogenes antigens
EP1615950A2 (en) * 2003-04-15 2006-01-18 Intercell AG S. pneumoniae antigens
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CA2808919C (en) 2005-12-22 2016-04-19 Glaxosmithkline Biologicals S.A. Streptococcus pneumoniae capsular saccharide vaccine
KR101579947B1 (ko) 2007-06-26 2015-12-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
AU2008280799B2 (en) * 2007-07-23 2013-07-11 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
WO2009127676A1 (en) * 2008-04-16 2009-10-22 Glaxosmithkline Biologicals S.A. Vaccine
JP5722782B2 (ja) 2008-09-26 2015-05-27 ナノバイオ コーポレーション ナノエマルジョン治療用組成物及びその使用方法
EP2424562B1 (en) 2009-04-30 2015-10-07 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
KR101512053B1 (ko) 2009-09-03 2015-04-28 화이자 백신스 엘엘씨 Pcsk9 백신
GB201003920D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
JP6046632B2 (ja) 2010-12-03 2016-12-21 サノフィ パストゥール リミテッドSanofi Pasteur Limited 肺炎球菌に対する免疫用組成物
SG10201600435UA (en) 2011-01-20 2016-02-26 Genocea Biosciences Inc Vaccines And Compositions Against Streptococcus Pneumoniae
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
AU2012257771C1 (en) 2011-05-17 2015-12-03 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
US10161940B2 (en) * 2012-01-05 2018-12-25 Deutsches Krebsforschungszentrum Means and methods for treating or diagnosing IDH1 R132H mutant-positive cancers
EP2931743A4 (en) * 2012-12-14 2016-08-03 Sanofi Pasteur Ltd METHOD FOR ASSESSING IMMUNOGENICITY
KR102157200B1 (ko) 2014-01-21 2020-09-21 화이자 인코포레이티드 접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3096783B1 (en) 2014-01-21 2021-07-07 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
SI3583947T1 (sl) 2014-01-21 2024-01-31 Pfizer Inc. Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
ES2930318T3 (es) 2014-02-14 2022-12-09 Pfizer Conjugados glucoproteicos inmunogénicos
IL252915B2 (en) 2015-01-15 2024-04-01 Pfizer Immunogenic compositions for use in pneumococcal vaccines
IL303998A (en) 2015-07-21 2023-08-01 Pfizer Immunogenic preparations containing conjugated capsular sugar antigens, kits containing them and their uses
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
RU2762723C2 (ru) 2017-01-20 2021-12-22 Пфайзер Инк. Иммуногенные композиции для применения в пневмококковых вакцинах
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
WO2020208502A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
AU2020323498A1 (en) 2019-07-31 2022-03-03 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
US20230000966A1 (en) 2019-11-01 2023-01-05 Pfizer Inc. Escherichia coli compositions and methods thereof
BR112022015796A2 (pt) 2020-02-21 2022-10-11 Pfizer Purificação de sacarídeos
CN115605498A (zh) 2020-02-23 2023-01-13 辉瑞公司(Us) 大肠杆菌组合物及其方法
EP4232593A1 (en) 2020-10-22 2023-08-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
TW202227467A (zh) 2020-10-27 2022-07-16 美商輝瑞大藥廠 大腸桿菌組合物及其方法
WO2022097010A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
JP2024517780A (ja) 2021-05-03 2024-04-23 ファイザー・インク 細菌およびベータコロナウイルス感染症に対するワクチン接種
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
PH12023553205A1 (en) 2021-05-28 2024-02-19 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2022249107A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
KR20250008122A (ko) 2022-05-11 2025-01-14 화이자 인코포레이티드 보존제를 갖는 백신 제형의 제조 방법
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
KR20250107930A (ko) 2022-11-22 2025-07-14 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
KR20250113501A (ko) 2022-12-01 2025-07-25 화이자 인코포레이티드 폐렴구균 접합체 백신 제형
EP4661911A1 (en) 2023-02-10 2025-12-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121038808A (zh) 2023-03-30 2025-11-28 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其用途
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
JP3976334B2 (ja) * 1993-03-19 2007-09-19 リンダール, グンナル B群れんさ球菌の多くの菌株に対する免疫を与える細胞表面タンパク質であるタンパク質Rib、そのタンパク質の精製方法、薬剤キットおよび医薬組成物
CZ394297A3 (cs) * 1995-06-07 1998-04-15 Biochem Vaccines Inc. Streptokokové proteiny teplotního šoku ze skupiny HSP70
US5928895A (en) * 1996-09-24 1999-07-27 Smithkline Beecham Corporation IgA Fc binding protein
US5882896A (en) * 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
DE69739981D1 (de) * 1996-10-31 2010-10-14 Human Genome Sciences Inc Streptococcus pneumoniae-Antigene und Impfstoffe
KR20010024299A (ko) * 1997-09-24 2001-03-26 리전츠 오브 더 유니버스티 오브 미네소타 스트렙토코쿠스 뉴모니애로부터의 사람 보체 c3 분해단백질분해효소
AU770378B2 (en) * 1998-04-23 2004-02-19 Uab Research Foundation Pneumococcal surface protein C(PspC), epitopic regions and strain selection thereof, and uses therefor
EP1100921B1 (en) * 1998-07-27 2007-05-02 Sanofi Pasteur Limited Streptococcus pneumoniae proteins and nucleic acid molecules
EP1144640A3 (en) * 1998-07-27 2001-11-28 Microbial Technics Limited Nucleic acids and proteins from streptococcus pneumoniae
CA2343931A1 (en) * 1998-09-24 2000-03-30 Regents Of The University Of Minnesota Human complement c3-degrading polypeptide from streptococcus pneumoniae
PT1140157E (pt) * 1998-12-21 2009-05-06 Medimmune Inc Proteínas de streptococcus pneumoniae e fragmentos imunogénicos para vacinas
CN100398653C (zh) * 1998-12-23 2008-07-02 益得生物医学公司 新颖的链球菌抗原

Similar Documents

Publication Publication Date Title
JP2002533123A5 (enExample)
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
WO2001098334A3 (en) Streptococcus antigens
WO2000039299A3 (en) Streptococcus antigens
CY1106875T1 (el) Αντιγονικα πεπτιδια απο neisseria
BR0314093A (pt) Proteìnas de fusão de transferrina modificada-anticorpo
HUS1600019I1 (hu) Polipeptideket tartalmazó készítmények
WO1999042588A3 (en) Group b streptococcus antigens
EP2343318A3 (en) Antibodies binding to a C-terminal fragment of apolipoprotein E
EP2287201A3 (en) RS7 antibodies
CA2103887A1 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
UA87093C2 (ru) ГУМАНИЗИРОВАННЫЙ ИММУНОГЛОБУЛИН, КОТОРЫЙ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С БЕТА-АМИЛОИДНЫМ ПЕПТИДОМ (Аβ)
ATE125821T1 (de) Vakzin gegen hepatitis b.
WO2000076540A3 (en) Streptococcus pneumoniae proteins and vaccines
NZ296564A (en) Method of improving antigenicity of antigens or haptens, fusion with rsv peptides; vaccines, vectors, nucleotides
IL127595A0 (en) Polypeptides capable of forming antigen binding structures with specificity for the rhesus D antigens the DNA encoding them and the process for their preparation and use
AU2002354806A1 (en) Parathyroid hormone antibodies and related methods
WO2000025722A3 (en) ENHANCED VACCINES COMPRISING SELF AND NON-SELF IgE PORTIONS OR DIMERIC ANTIGENS
WO2005028618A3 (en) Immunogenic compositions for streptococcus agalactiae
NZ547629A (en) Antibodies binding to conformationally discriminating epitopes of human IGG Fc receptor IIb and IIb
WO2001081380A3 (en) Immunogenic pneumococcal protein and vaccine compositions thereof
MY141459A (en) Recombinant anti-idiotypic antibodies
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
EP1326895B8 (fr) Anticorps monoclonaux diriges contre des virus de l'hepatite b
DE69115104D1 (de) Composition comprising at least two different antibodies or fragments thereof.